Summary
A Phase II clinical evaluation of 4′-epi-doxorubicin has been carried out in 100 patients with various types of solid tumors. Hematopoietic toxicity was dose-limiting but reversible and of mild to moderate degree. Other acute toxic manifestations such as vomiting and alopecia were qualitatively similar to those usually reported for doxorubicin, but lower in frequency and less severe. A number of responding patients received cumulative doses of 4′-epi-doxorubicin in excess of 500 mg/m2. One patient manifested reversible clinical congestive heart failure at cumulative dose of 1,080 mg/m2. Therapeutic activity has been observed in breast carcinoma, in rectal carcinoma and in melanoma. In chemoresistant tumors as rectal cancer and melanoma 4′-epi-doxorubicin deserves further study.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Young RC, Ozols RE, Myers CE: The anthracyclines antineoplastic drugs. N Engl J Med 305:139–153, 1981
Arcamone F, Penco S, Vigevani A, Redaelli S, Franchi S, Di Marco A, Casazza AM, Dasdia T, Formelli F, Necco A, Soranzo C: Synthesis and antitumor properties of new glycosides of daunomycinone and adriamycinone. J Med Chem 18:703–707, 1975
Casazza AM, Di Marco A, Bertazzoli C, Formelli F, Giuliani F, Pratesi G: Antitumor activity, toxicity and pharmacological properties of 4′-epiadriamycin. Current Chemotherapy. Proceedings of the 10th International Congress of Chemotherapy 2, 1978, pp 1257–1260
Casazza AM, Di Marco A, Bonadonna G, Bonfante V, Bertazzoli C, Bellini O, Pratesi G, Sala L, Ballernini L: Effects of modifications in position 4 of the chromophore or in position 4′ of the aminosugar, on the antitumor activity and toxicity of daunorubicin and doxorubicin. In: Crooke ST, Reich SD (eds) Anthracyclines: Current Status and New Developments. Academic, Press, 1980, 23, pp 403–429
Bonfante V, Bonadonna G, Villani F, Di Fronzo G, Martini A, Casazza AM: Preliminary phase I study of 4′-epiadriamycin. Cancer Treat Rep 63:915–918, 1979
Schauer PK, Wittes RE, Gralla RJ, Casper ES, Young CW; A phase I trial of 4′-epi-adriamycin. Cancer Clin Trials 4:433–437, 1981
Bonfante V, Villani F, Bonadonna G: Toxic and therapeutic activity of 4′-epi-doxorubicin. Tumori 68:105–111, 1982
Blum RH, Carter SK: Adriamycin, a new anticancer drug with significant clinical activity. Ann Intern Med 80:249–259, 1974
Bonadonna G, Beretta G, Tancini G, Brambilla C, Bajetta E, De Palo GM, De Lena M, Fossati Bellani F, Gasparini M, Valagussa P, Veronesi U: Adriamycin (NSC-123127) studies at the Istituto Nazionale Tumori, Milan. Cancer Chemother Rep (part 3) 6:231–245, 1975
Broggini M, Colombo T, Martini A, Donelli MG: Studies on the comparative distribution and biliary excretion of doxorubicin and 4′-epi-doxorubicin in mice and rats. Cancer Treat Rep 63:897–904, 1980
Martini A, Isetta AM, Moro E, Natale N, Piazza E: Studio farmacocinetico nell'uomo sulla 4′-epi-doxorubicina in confronto a doxorubicina. Tumori 6 (2), Suppl A, no 40, 1980 (Abstract)
Camaggi CM, Strocchi E, Tamassia V, Martoni A, Giovannini M, Infelice C, Canova N, Marraro D, Martini A, Pannuti F: Pharmacokinetics studies of 4′-epi-doxorubicin in cancer patients with normal and impaired renal function and with hepatic metastasis. Cancer Treat Rep 66:1819–1824, 1982
Weenen H, Lankelma J, Penders PGM, McWie JG, Ten Bokkel Huinink WW, de Planque MM, Pinedo HM: Pharmacokinetics of 4′-epi-doxorubicin in man. Invest N Drugs 1:59–64, 1983
Von Hoff DD, Layard MW, Basa P, Davis HL, Von Hoff AL, Rozencweig M, Muggia F: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710–717, 1979
O'Bryan RM, Baker LH, Gottlieb JE, Rivkin SE, Balcerzak SP, Grumet GN, Salmon SE, Moon TE, Hoogstraten B: Dose response evaluation of adriamycin in human neoplasia. Cancer 39:1940–1948, 1977
Young CW, Wittes RE, Jain K, Casper ES: Clinical evaluation of 4′-epi-doxorubicin. 13th International Congress of Chemotherapy, Vienna (Austria), August 28th–September 2nd, 1983
Wittes RE, Jain K, Kaufman R, Currie V, Hakes T, Bosl G, Benedetto P, Young C: A randomized comparison of 4′-epidoxorubicin (4′-ED) and doxorubicin (DOX) in advanced breast cancer. Proc Am Soc Clin Oncol 2:109, 1983 (Abstract)
Fossa SD, Wik B, Bae E, Lien HN: Phase II study of 4′-epidoxorubicin in metastatic renal cancer. Cancer Treat Rep 66:1219–1221, 1982
Kolaric K, Potrebica V, Cervek Y: Phase II clinical trial of 4′-epi-doxorubicin in metastatic solid tumors. J Cancer Res Clin Oncol 1983, (in press)
Falkson G, Falkson HC, Vorobiof DA, Pretoriuss HL, Falkson CB: A phase Ii study of 4′-epi-doxorubicin in colorectal cancer. 13th International Congress of Chemotheapy, Vienna (Austria), August 28th–September 2nd, 1983
Robustelli Della Cuna G, Pavesi L, Cuzzoni Q, Ganzina F, Tramarin R: A phase II study of 4′-epi-adriamycin in advanced solid tumors. Curr Chemother Immunother 2:1462–1464, 1982
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cuna, G.R.D., Pavesi, L., Preti, P. et al. Clinical evaluation of 4′-epi-doxorubicin in advanced solid tumors. Invest New Drugs 1, 349–353 (1983). https://doi.org/10.1007/BF00177421
Issue Date:
DOI: https://doi.org/10.1007/BF00177421